Session » T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 711

1,25(OH)₂D₃ Inhibits Th17 Cytokine Production and RORγt Expression Through GATA3/IL4-Dependent and -Independent Mechanisms

Abstract Number: 712

Increased IL-23 Receptor Expression Is Observed On KIR3DL2+ CD4+ T Cells In Ankylosing Spondylitis and Correlates With IL-23R Polymorphisms

Abstract Number: 713

Interferon Regulatory Factor 2 Haploinsufficiency Deteriorates Imiquimod-Induced Psoriasis-Like Skin Inflammation

Abstract Number: 714

Combination Blocking Of Interleukin-6 and Interleukin-21 In Experimental Arthritis Inhibits Their Redundant Role In T Helper 17-Driven Joint Pathology

Abstract Number: 715

Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression In CD4+ T Cells

Abstract Number: 716

The Active Metabolite Of Spleen Tyrosine Kinase Inhibitor Fostamatinib Abrogates The T Cell Priming Capacity Of Dendritic Cells

Abstract Number: 717

Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th17 Responses But Preserved Oral Candida Albicans Protective Immunity

Abstract Number: 718

Mesenchymal Stem Cells and Skin Fibroblasts Both Suppress Early Steps In T Cell Activation In a Nitric-Oxide Dependent Manner

Abstract Number: 719

Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)

Abstract Number: 720

Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients

Abstract Number: 721

T Cell Activation Induces Increased mRNA Expression Of The Splicing Factor SF2/ASF But Simultaneous Protein Downregulation Via Proteasome Mediated Degradation

Abstract Number: 722

BAFF Promotes T Follicular Helper Cell Development and Germinal Center Generation In Mice

Abstract Number: 723

Abatacept Is Highly Effective At Inhibiting T Cell Priming and Induces a Unique Transcriptional Profile In CD4⁺t Cells

Abstract Number: 724

Dose-Dependent Suppression Of Cytokine Production From T Cells By a Novel Phosphoinositide 3-Kinase Delta Inhibitor

Abstract Number: 725

Localization At The Immunological Synapse Of Adaptor Protein Grb2 and PLC Gamma-1 In Non-Stimulated Peripheral Blood T Lymphocytes From Patients With Systemic Lupus Erythematosus Suggests An In Vivo dysregulated Activation State

Abstract Number: 726

Tofacitinib Does Not Inhibit Dendritic Cell Maturation and T Cell Proliferation In Vitro

Abstract Number: 727

Adiponectin Promotes The Differentiation Of naïve T Cell To Th17 Cell and Aggravates Collagen-Induced Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.